Clinical outcome of pegylated interferon and ribavirin therapy for chronic hepatitis C / 대한간학회지
The Korean Journal of Hepatology
; : 36-45, 2008.
Article
in Korean
| WPRIM (Western Pacific)
| ID: wpr-160191
Responsible library:
WPRO
ABSTRACT
BACKGROUND/AIMS:
The purpose of this study is to elucidate the efficacy and safety of combined peginterferon and ribavirin therapy in Korean patients with chronic HCV infection.METHODS:
We retrospectively analyzed the clinical records of 84 patients. Thirty five patients with genotype 1 HCV infection were treated with peginterferon alpha-2a 180 microgram/week and ribavirin 1,000-1,200 mg/day for 48 weeks, and 49 patients with genotype non-1 were treated with peginterferon alpha-2a 180 microgram/week and ribavirin 800 mg/day for 24 weeks.RESULTS:
An early virologic response was seen in 87.0% of patients with genotype 1 HCV. An end of treatment response (ETR) was seen in 82.6% and 97.6% of patients with genotype 1 and genotype non-1, respectively. An overall sustained virologic response (SVR) was seen in 53 patients (82.8%) of the 64 patients in 16 (69.6%) of 23 patients with genotype 1 and in 37 (90.2%) of 41 patients with genotype non-1. An end of treatment biochemical response was seen in 58 patients (90.6%) [genotype 1, 20 patients (87.0%); genotype non-1, 38 patients (92.7%)], and a sustained biochemical response was achieved in 49 patients (76.6%) [genotype 1, 14 patients (60.9%); genotype non-1, 35 patients (85.4%)]. Independent factors affecting an SVR were HCV genotype and the baseline HCV RNA level.CONCLUSIONS:
This study shows that a combination therapy of peginterferon and ribavirin is highly effective for chronic HCV infection, producing a high SVR and ETR.
Full text:
Available
Health context:
SDG3 - Health and Well-Being
Health problem:
Target 3.3: End transmission of communicable diseases
Database:
WPRIM (Western Pacific)
Main subject:
Antiviral Agents
/
Polyethylene Glycols
/
Ribavirin
/
Treatment Outcome
/
Hepatitis C, Chronic
/
Reverse Transcriptase Polymerase Chain Reaction
/
Drug Therapy, Combination
/
Interferon alpha-2
/
Genotype
Limits:
Adult
/
Female
/
Humans
/
Male
Language:
Korean
Journal:
The Korean Journal of Hepatology
Year:
2008
Document type:
Article